Top

Published in:

01-02-2015 | Original Article

Educational paper: therapy of infantile haemangioma—history and current state (part II)

Authors: Sherief R. Janmohamed, Gerard C. Madern, Peter C. J. de Laat, Arnold P. Oranje

Published in: European Journal of Pediatrics | Issue 2/2015

Abstract

Infantile haemangioma (IH) is the most frequent tumour of infancy. Although it is benign and self-limiting, severe complications can arise due to localisation and fast tumour growth. Also, IHs leave scars after regression in more than half of the cases. Management and therapy of IH have changed greatly after 2008. This update provides an overview of the older therapy options before 2008, which mainly consisted of the administration of corticosteroids, and discusses the modern management with new therapy options such as β-blockers (both systemically and topically).

Conclusion: β-blockers are promising and are currently preferred above corticosteroids, but β-blockers still do not give a definitive treatment.

Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R (2002) Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 360(9332):521–527PubMedCrossRef

Bauland CG, Luning TH, Smit JM, Zeebregts CJ, Spauwen PH (2011) Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 127(4):1643–1648PubMedCrossRef

Boehm DK, Kobrinsky NL (1993) Treatment of cavernous hemangioma with vincristine. Ann Pharmacother 27(7–8):981PubMed

Bonifazi E, Mazzotta F, Colonna V (2010) Topical propranolol in the superficial infantile hemangioma of the skin. Eur J Pediatr Dermatol 20:247–251

Boon LM, MacDonald DM, Mulliken JB (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104(6):1616–1623PubMedCrossRef

Boye E, Jinnin M, Olsen BR (2009) Infantile hemangioma: challenges, new insights, and therapeutic promise. J Craniofac Surg 20(Suppl 1):678–684PubMedCrossRef

Breur JM, de Graaf M, Breugem CC, Pasmans SG (2011) Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 28(2):169–171PubMedCrossRef

Bruckner AL, Frieden IJ (2003) Hemangiomas of infancy. J Am Acad Dermatol 48(4):477–493, quiz 494–476PubMedCrossRef

Bruckner AL, Frieden IJ (2006) Infantile hemangiomas. J Am Acad Dermatol 55(4):671–682PubMedCrossRef

10.

Chan H, McKay C, Adams S, Wargon O (2013) RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 131(6):e1739–e1747PubMedCrossRef

11.

Chan YC (2004) Current treatment practices in the management of cutaneous haemangioma. Expert Opin Pharmacother 5(9):1937–1942PubMedCrossRef

12.

Chantasart D, Hao J, Li SK (2013) Evaluation of skin permeation of beta-blockers for topical drug delivery. Pharm Res 30(3):866–877PubMedCrossRef

13.

Chiller KG, Passaro D, Frieden IJ (2002) Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 138(12):1567–1576PubMedCrossRef

14.

de Graaf M, Breur JM, Raphael MF, Vos M, Breugem CC, Pasmans SG (2011) Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 65(2):320–327PubMedCrossRef

15.

Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, MacLellan-Tobert S, Mancini AJ, Metry D, Puttgen KB, Seefeldt M, Sidbury R, Ward KM, Blei F, Baselga E, Cassidy L, Darrow DH, Joachim S, Kwon EK, Martin K, Perkins J, Siegel DH, Boucek RJ, Frieden IJ (2013) Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 131(1):128–140PubMedCentralPubMedCrossRef

16.

Du W, Gerald D, Perruzzi CA, Rodriguez-Waitkus P, Enayati L, Krishnan B, Edmonds J, Hochman ML, Lev DC, Phung TL (2013) Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Lab Invest 93(10):1115–1127PubMedCrossRef

17.

Enjolras O, Riche MC, Merland JJ, Escande JP (1990) Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 85(4):491–498PubMed

18.

Ezekowitz A, Mulliken J, Folkman J (1991) Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 79(Suppl 1):67–68PubMedCrossRef

19.

Fost NC, Esterly NB (1968) Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 72(3):351–357PubMedCrossRef

20.

Frieden IJ (2011) Infantile hemangioma research: looking backward and forward. J Invest Dermatol 131(12):2345–2348PubMedCrossRef

21.

Frieden IJ, Drolet BA (2009) Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol 26(5):642–644PubMedCrossRef

22.

Giron-Vallejo O, Lopez-Gutierrez JC, Fernandez-Pineda I, Mendez NA, Ruiz Jimenez JI (2010) Dental caries as a side effect of infantile hemangioma treatment with propranolol solution. Pediatr Dermatol 27(6):672–673PubMedCrossRef

23.

Glassberg E, Lask G, Rabinowitz LG, Tunnessen WW Jr (1989) Capillary hemangiomas: case study of a novel laser treatment and a review of therapeutic options. J Dermatol Surg Oncol 15(11):1214–1223PubMedCrossRef

24.

Greenberger S, Bischoff J (2011) Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med 1(1):a006460PubMedCentralPubMedCrossRef

25.

Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J (2010) Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 362(11):1005–1013PubMedCentralPubMedCrossRef

26.

Guo S, Ni N (2010) Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 128(2):255–256PubMedCrossRef

27.

Haggstrom AN, Beaumont JL, Lai JS, Adams DM, Drolet BA, Frieden IJ, Garzon MC, Holland KE, Horii KA, Lucky AW, Mancini AJ, Metry DW, Morel KD, Newell BD, Nopper AJ, Siegel D, Swigonski NL, Cella D, Chamlin SL (2012) Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol 148(2):197–202PubMedCrossRef

28.

Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Newell B, Nopper AJ, Frieden IJ (2006) Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 118(3):882–887PubMedCrossRef

29.

Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA (2010) Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 146(7):775–778PubMedCrossRef

30.

Janmohamed SR, Brinkhuizen T, Madern GC, den Hollander JC, de Laat PC, Van Steensel MA, Oranje AP (2014) Support for the hypoxia theory in the pathogenesis of infantile haemangioma. Clin Exp Dermatol doi:10.1007/s00431-014-2404-5

31.

Janmohamed SR, de Laat PC, Madern GC, Dorresteijn EM, Jan Danser AH, Oranje AP (2012) Treating hemangioma of infancy with beta-blockers: is there really a risk of hypotension? J Am Acad Dermatol 67(2):315–316, author reply 316–318PubMedCrossRef

32.

Janmohamed SR, de Laat PC, Madern GC, Oranje AP (2011) Do we have to check glucose in patients with haemangioma of infancy treated with beta-blockers? J Eur Acad Dermatol Venereol 25(12):1490PubMedCrossRef

33.

Janmohamed SR, de Waard-van der Spek FB, Madern GC, de Laat PC, Hop WC, Oranje AP (2011) Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol 36(7):715–723PubMedCrossRef

34.

Janmohamed SR, Madern GC, de Laat PC, Oranje AP (2014) Educational paper: pathogenesis of infantile hemangioma—an update (part I). Eur J Pediatr doi:10.1007/s00431-014-2404-5

35.

Janmohamed SR, Madern GC, Nieuwenhuis K, de Laat PC, Oranje AP (2012) Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol. Pediatr Surg Int 28(4):393–398PubMedCentralPubMedCrossRef

36.

Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, Tepper OM, Gurtner GC (2007) Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 27(12):2664–2670PubMedCrossRef

37.

Kum JJ, Khan ZA (2014) Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis. Pediatr Res 75(3):381–388PubMedCentralPubMedCrossRef

38.

Lawley LP, Siegfried E, Todd JL (2009) Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 26(5):610–614PubMedCrossRef

39.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358(24):2649–2651PubMedCrossRef

40.

Luu M, Frieden IJ (2013) Haemangioma: clinical course, complications and management. Br J Dermatol 169(1):20–30PubMedCrossRef

41.

Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, Glover M, Giardini A, Harper JI (2010) Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 162(2):466–468PubMedCrossRef

42.

Marqueling AL, Oza V, Frieden IJ, Puttgen KB (2013) Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol 30(2):182–191PubMedCrossRef

43.

Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr (2002) Infantile hemangioma: clinical resolution with 5 % imiquimod cream. Arch Dermatol 138(7):881–884, discussion 884

44.

Medici D, Olsen BR (2012) Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One 7(8):e42913PubMedCentralPubMedCrossRef

45.

Mouhari-Toure A, Azoumah KD, Tchamdja K, Saka B, Kombate K, Tchangai-Walla K, Pitche P (2013) [Rapid regression of infantile haemangioma with 2% propranolol ointment] Regression rapide d'un hemangiome infantile sous propranolol topique a 2 %. Ann Dermatol Venereol 140(6–7):462–464PubMedCrossRef

46.

Mulliken JB, Enjolras O (2004) Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 50(6):875–882PubMedCrossRef

47.

Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69(3):412–422PubMedCrossRef

48.

Mulliken JB, Young AE (1988) Treatment of hemangiomas vascular birthmarks: hemangiomas and malformations. WB Saunders, Philadelphia

49.

Munroe WP, Rindone JP, Kershner RM (1985) Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm 19(2):85–89PubMed

50.

Nguyen J, Fay A (2009) Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin Ophthalmol 24(3):178–184PubMedCrossRef

51.

Nieuwenhuis K, de Laat PC, Janmohamed SR, Madern GC, Oranje AP (2013) Infantile hemangioma: treatment with short course systemic corticosteroid therapy as an alternative for propranolol. Pediatr Dermatol 30(1):64–70PubMedCrossRef

52.

Oranje AP, Janmohamed SR, Madern GC, de Laat PC (2011) Treatment of small superficial haemangioma with timolol 0.5 % ophthalmic solution: a series of 20 cases. Dermatology 223(4):330–334

53.

Perez-Valle S, Peinador M, Herraiz P, Saenz P, Montoliu G, Vento M (2010) Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr 99(2):311–315PubMedCrossRef

54.

Pope E, Chakkittakandiyil A (2010) Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 146(5):564–565PubMedCrossRef

55.

Puttgen KB, Summerer B, Schneider J, Cohen BA, Boss EF, Bauman NM (2013) Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Otol Rhinol Laryngol 122(9):550–554PubMedCrossRef

56.

Raphael MF, de Graaf M, Breugem CC, Pasmans SG, Breur JM (2011) Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol 65(2):420–421PubMedCrossRef

57.

Reiter MJ (2004) Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 47(1):11–33PubMedCrossRef

58.

Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, Taieb A, Léauté-Labrèze C (2009) Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 124(3):e423–e431PubMedCrossRef

59.

Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, Balmer C, Weibel L (2011) Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 170(4):493–501PubMedCrossRef

60.

Sharma VK, Fraulin FO, Dumestre DO, Walker L, Harrop AR (2013) Beta-blockers for the treatment of problematic hemangiomas. Can J Plast Surg 21(1):23–28PubMedCentralPubMed

61.

Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, Tomai M, Puscasiu E, Gugneja S, Paller AS (2003) Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 121(5):1205–1209PubMedCrossRef

62.

Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163(2):269–274PubMedCrossRef

63.

Verity DH, Rose GE, Restori M (2008) The effect of intralesional steroid injections on the volume and blood flow in periocular capillary haemangiomas. Orbit (Amsterdam, Netherlands) 27(1):41–47

64.

Weiss AH, Kelly JP (2008) Reappraisal of astigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology 115(2):390.e391–397.e391

65.

Wright TL, Bresnan MJ (1976) Radiation-induced cerebrovascular disease in children. Neurology 26(6 PT 1):540–543PubMedCrossRef

66.

Xu SQ, Jia RB, Zhang W, Zhu H, Ge SF, Fan XQ (2013) Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review. World J Pediatr 9(3):221–229PubMedCrossRef

Title: Educational paper: therapy of infantile haemangioma—history and current state (part II)
Authors: Sherief R. Janmohamed
Gerard C. Madern
Peter C. J. de Laat
Arnold P. Oranje
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 2/2015
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-014-2404-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Educational paper: therapy of infantile haemangioma—history and current state (part II)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Cognition and the risk of eating disorders in Spanish adolescents: the AVENA and AFINOS studies

Brain imaging findings and social/emotional problems in Israeli children with neurofibromatosis type 1

The association between resting heart rate and blood pressure among children and adolescents with different waist circumferences

Airflow limitation following cardiopulmonary exercise testing and heavy-intensity intermittent exercise in children with cystic fibrosis

High prevalence of vitamin D insufficiency/deficiency in Dutch multi-ethnic obese children

Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age: a randomized controlled trial